NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

NCT03399448 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Sponsor has terminated trial to pursue other targets.

Conditions

Multiple Myeloma
Melanoma
Synovial Sarcoma
Myxoid/Round Cell Liposarcoma

Interventions

BIOLOGICAL: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
DRUG: Cyclophosphamide
DRUG: Fludarabine
DEVICE: NY-ESO-1 expression testing

Sponsor

University of Pennsylvania

Collaborators

[object Object]
[object Object]